SPOTLIGHT: Myriad drug fails in trial


Myriad Genetics has dropped one of its development programs for an experimental therapy--MPC-7869--after it failed to perform better than a placebo in a clinical trial for prostate cancer. Myriad researchers say they will continue to study the drug as a therapy for Alzheimer's. They added that the drug was well tolerated in an elderly population. Report

Suggested Articles

The clamor for more transparency from the leading pandemic vaccine contenders has been getting louder.

The role gives one of the driving forces behind Bristol Myers Squibb’s $74 billion takeover of Celgene the chance to help build biotechs.

The appointment gives Sino-American biotech Brii the experience of a man who helped Gilead launch eight drugs in China in quick succession.